X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
chemotherapy (2) 2
disease-free survival (2) 2
female (2) 2
humans (2) 2
index medicus (2) 2
middle aged (2) 2
1st-line therapy (1) 1
abridged index medicus (1) 1
administration, intravenous (1) 1
administration, oral (1) 1
adult (1) 1
aged (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents, hormonal - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
aromatase inhibitors - administration & dosage (1) 1
brca1 protein - genetics (1) 1
brca2 protein - genetics (1) 1
breast - pathology (1) 1
breast cancer (1) 1
breast neoplasms - drug therapy (1) 1
breast neoplasms - mortality (1) 1
breast neoplasms - pathology (1) 1
cancer (1) 1
cancer therapies (1) 1
carboplatin - administration & dosage (1) 1
carcinoma (1) 1
cisplatin (1) 1
clinical medicine (1) 1
clinical trials (1) 1
combination (1) 1
deoxyribonucleic acid--dna (1) 1
diseases (1) 1
double-blind method (1) 1
drug administration schedule (1) 1
efficacy (1) 1
endocrine therapy (1) 1
endocrine-therapy (1) 1
enzyme inhibitors - administration & dosage (1) 1
enzyme inhibitors - adverse effects (1) 1
estradiol - analogs & derivatives (1) 1
estradiol - therapeutic use (1) 1
estrogen (1) 1
first-line therapy (1) 1
gene mutations (1) 1
hematology, oncology and palliative medicine (1) 1
hormones (1) 1
hospitals (1) 1
inhibition (1) 1
internal medicine (1) 1
letrozole (1) 1
liposomal doxorubicin (1) 1
maintenance therapy (1) 1
medical colleges (1) 1
medicine, general & internal (1) 1
metastasis (1) 1
molecular targeted therapy (1) 1
monosaccharides (1) 1
multicenter (1) 1
mutation (1) 1
neoplasm grading (1) 1
neoplasm recurrence, local (1) 1
neoplasms, cystic, mucinous, and serous - drug therapy (1) 1
neoplasms, cystic, mucinous, and serous - enzymology (1) 1
neoplasms, cystic, mucinous, and serous - mortality (1) 1
neoplasms, cystic, mucinous, and serous - pathology (1) 1
nitriles - therapeutic use (1) 1
oncology (1) 1
open-label (1) 1
ovarian cancer (1) 1
ovarian neoplasms - drug therapy (1) 1
ovarian neoplasms - enzymology (1) 1
ovarian neoplasms - genetics (1) 1
ovarian neoplasms - mortality (1) 1
ovarian neoplasms - pathology (1) 1
paclitaxel - administration & dosage (1) 1
patients (1) 1
pharmaceutical industry (1) 1
phthalazines - administration & dosage (1) 1
phthalazines - adverse effects (1) 1
piperazines - administration & dosage (1) 1
piperazines - adverse effects (1) 1
poly polymerase inhibitors (1) 1
poly polymerases - metabolism (1) 1
polymerase (1) 1
postmenopausal women (1) 1
postmenopause (1) 1
product development (1) 1
receptors, estrogen - analysis (1) 1
relapse (1) 1
solid tumors (1) 1
sugars (1) 1
superior (1) 1
survival (1) 1
tamoxifen (1) 1
time factors (1) 1
treatment outcome (1) 1
triazoles - therapeutic use (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10063, pp. 2997 - 3005
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.